Date
Title
View
22 Apr 20
4basebio AG: 4basebio provides Phi29 DNA polymerase variants and expertise to develop improved detection system for SARS-CoV-2 infection
View
21 Feb 20
4basebio AG announces allotment ratio and final number of shares for the share buy back
View
21 Feb 20
4basebio AG: 4basebio AG announces allotment ratio and final number of shares for the share buy back
View
18 Feb 20
Notification of the allotment ratio for the share buy back
View
14 Feb 20
4basebio AG: 4basebio AG announces results of the public share buyback offerand final purchase price for the share buy back (news with additional features)
View
10 Feb 20
4basebio AG: 4basebio AG decides to increase the public share buyback offer volume from 2,056,452 to 5,230,726 shares (news with additional features)
View
21 Jan 20
4basebio AG: 4basebio AG decides to buy back 2 million treasury shares (news with additional features)
View
21 Jan 20
4basebio AG: Expedeon AG completes change of name to 4basebio AG and of ticker symbol to 4BSB (news with additional features)
View
02 Jan 20
Expedeon AG: Expedeon AG and Abcam plc close EUR 120 million transaction (news with additional features)
View
19 Dec 19
Expedeon AG: Expedeon shareholders approve sale of proteomics & immunotherapy business and name change to 4basebio AG (news with additional features)
View
21 Nov 19
Expedeon AG: Expedeon to Present at the Deutsches Eigenkapitalforum in Frankfurt / Main (news with additional features)
View
20 Nov 19
Expedeon AG: Expedeon AG information on EUR 120 million deal with Abcam on dedicated transaction website (news with additional features)
View